← Browse by Condition
Medical Condition
non small cell lung carcinoma
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 3, Phase 1, Phase 2
NCT07284186 Phase 1
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Enrollment
155 pts
Location
United States
Sponsor
Plexium, Inc.
NCT04853342 Phase 3
Recruiting
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Enrollment
318 pts
Location
China
Sponsor
Allist Pharmaceuticals, Inc.
NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Location
United States, Austr...
Sponsor
PMV Pharmaceuticals, Inc